Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie 2/2009

01-04-2009 | Klinische les

Cardiale neveneffecten van cholinesteraseremmers: een reden tot terughoudendheid in voorschrijven?

Auteurs: A. M. Salarbaks, C. M. Boomkamp-Snoeren, E. van Puijenbroek, P. A. F. Jansen, Dr R. J. van Marum

Gepubliceerd in: Tijdschrift voor Gerontologie en Geriatrie | Uitgave 2/2009

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Cholinesteraseremmers worden voorgeschreven bij de behandeling van lichte tot matig ernstige dementie. Er is nog relatief weinig bekend over de veiligheid van deze groep geneesmiddelen bij patiënten met cardiale aandoeningen. In deze les presenteren wij twee patiënten waarbij het starten van een cholinesteraseremmer werd gevolgd door een acute cardiovasculaire aandoening. Wij beschrijven de cardiale effecten van cholinesteraseremmers en geven informatie over gerapporteerde cardiale bijwerkingen en potentiele geneesmiddeleninteracties met cardiale consequenties. Hoewel het absolute risico op cardiale bijwerkingen gering is, lijkt het verstandig de cardiale functie goed te monitoren bij patiënten met cardiale problemen, met name indien zij medicatie gebruiken die de negatieve potentiële cardiale effecten van cholinesteraseremmers kunnen versterken.
Literatuur
1.
go back to reference Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-47. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-47.
2.
go back to reference Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008;117(2):232-43. Epub 2007 Dec 20. Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther. 2008;117(2):232-43. Epub 2007 Dec 20.
3.
go back to reference Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453-78. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21(7):453-78.
4.
go back to reference Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL.Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies Vidal, (British National Formulary. Drug Saf.) 2007;30(11):1063-71. Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL.Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies Vidal, (British National Formulary. Drug Saf.) 2007;30(11):1063-71.
5.
go back to reference Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947-63. Bentué-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs. 2003;17(13):947-63.
6.
go back to reference Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease—from basic research to bedside. Curr Alzheimer Res. 2004 Nov;1(4):315-21. Masuda Y. Cardiac effect of cholinesterase inhibitors used in Alzheimer's disease—from basic research to bedside. Curr Alzheimer Res. 2004 Nov;1(4):315-21.
7.
go back to reference Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42(5):558-568 Morganroth J, Graham S, Hartman R, Anand R. Electrocardiographic effects of rivastigmine. J Clin Pharmacol 2002; 42(5):558-568
8.
go back to reference Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60(6):639-645. Ballard C, Lane R, Barone P, Ferrara R, Tekin S. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006;60(6):639-645.
9.
go back to reference Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321(7274):1445-1449 Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321(7274):1445-1449
10.
go back to reference McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15(4):183-188 McLaren AT, Allen J, Murray A, Ballard CG, Kenny RA. Cardiovascular effects of donepezil in patients with dementia. Dement Geriatr Cogn Disord 2003; 15(4):183-188
11.
go back to reference Bordier P, Garrigue S, Lanusse S et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.CNS Drugs 2006; 20(5):411-417. Bordier P, Garrigue S, Lanusse S et al. Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.CNS Drugs 2006; 20(5):411-417.
12.
go back to reference Leentjes AFG, Kragten JA. Totaal atrioventriculair blok tijdens behandeling met galantamine. Nederlands Tijdschrift voor Geneeskunde.2006; 150:563-566. Leentjes AFG, Kragten JA. Totaal atrioventriculair blok tijdens behandeling met galantamine. Nederlands Tijdschrift voor Geneeskunde.2006; 150:563-566.
13.
go back to reference Kayrak M, Yazici M, Ayhan SS, Koc F, Ulgen MS. Complete atrioventricular block associated with rivastigmine therapy. Am J Health Syst Pharm. 2008;65(11):1051-3. Kayrak M, Yazici M, Ayhan SS, Koc F, Ulgen MS. Complete atrioventricular block associated with rivastigmine therapy. Am J Health Syst Pharm. 2008;65(11):1051-3.
14.
go back to reference Walsh E, Dourish J. Prolonged QT interval with rivastigmine. Br J Psychiatry 2002; 180:466. Walsh E, Dourish J. Prolonged QT interval with rivastigmine. Br J Psychiatry 2002; 180:466.
15.
go back to reference Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother. 2008;42(2):278-83. Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother. 2008;42(2):278-83.
16.
go back to reference Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J. 2006;23(8):641-2. Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J. 2006;23(8):641-2.
17.
go back to reference Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ,Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024-2035. Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Mayorga AJ,Wang D, Brashear HR, Nye JS; The GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008;70(22):2024-2035.
18.
go back to reference Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR,Berlin JA, Battisti WP, Kavanagh S. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand. 2008 Jun 1. [Epub ahead of print] Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Brashear HR,Berlin JA, Battisti WP, Kavanagh S. Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol Scand. 2008 Jun 1. [Epub ahead of print]
19.
go back to reference López-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing. 2006;35(4):365-71. López-Pousa S, Olmo JG, Franch JV, Estrada AT, Cors OS, Nierga IP, Gelada-Batlle E. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine. Age Ageing. 2006;35(4):365-71.
20.
go back to reference Roisin T., van Ermen A., Rogiers A. Cardiac Adverse Effects with Cholinesterase Inhibitors. (abstract no 34). Drug Safety 2006;29(10):911-1011 Roisin T., van Ermen A., Rogiers A. Cardiac Adverse Effects with Cholinesterase Inhibitors. (abstract no 34). Drug Safety 2006;29(10):911-1011
21.
go back to reference Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2):239-45. Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics. 1981;30(2):239-45.
Metagegevens
Titel
Cardiale neveneffecten van cholinesteraseremmers: een reden tot terughoudendheid in voorschrijven?
Auteurs
A. M. Salarbaks
C. M. Boomkamp-Snoeren
E. van Puijenbroek
P. A. F. Jansen
Dr R. J. van Marum
Publicatiedatum
01-04-2009
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Gerontologie en Geriatrie / Uitgave 2/2009
Print ISSN: 0167-9228
Elektronisch ISSN: 1875-6832
DOI
https://doi.org/10.1007/BF03079564

Andere artikelen Uitgave 2/2009

Tijdschrift voor Gerontologie en Geriatrie 2/2009 Naar de uitgave

Congresagenda

Congresagenda

Recente onderzoeksliteratuur

Recente onderzoeksliteratuur

Signalementen

Signalementen